Compare Sanofi SA (SNY) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Unity Software Inc — how do they compare? Sanofi SA trades at $40.1 (market cap $95.18B), while Unity Software Inc trades at $46.06 (market cap $20.20B). The key difference: Sanofi SA is far larger — about 4.7× Unity Software Inc's market cap, and Sanofi SA pays a 6.01% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Unity Software Inc for 50 Days on average.
| SNY | U | |
|---|---|---|
Market Cap | $95.18B | $20.20B |
Volume | 2,995,646 | 15,432,191 |
Sector | Health | Technology |
52-Week High | $52.34 | $49.47 |
52-Week Low | $39.51 | $17.13 |
Typical Hold Time | 94 Days | 50 Days |
Enterprise Value | $114.48B | $20.08B |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Unity Software (U) trades at $45.44, up 1.09% on the day, with a bullish technical signal and strong analyst support. The stock is near its pivot point of $45, with immediate resistance at $46. Fundamentally, revenue reached $1.85B in 2025, but the company reported a net loss of -$402.77M, though losses are narrowing year-over-year. Recent news highlights momentum from Meta VR Glasses support and positive sector sentiment.
Outlook: Strong buy consensus (82% of analysts) and a $46.54 price target suggest upside, but persistent losses and high valuation ratios pose risks. Investment appeal hinges on revenue growth and path to profitability, while competitive and execution risks remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
